Coverage Map

Learn About Your Coverage Options

#AccessForAll is our advocacy initiative to ensure equitable and universal access to diabetes devices for all Canadians, regardless of age. We aim to support the T1D community to increase both public and private coverage for advanced glucose monitors (Flash CGM and Continuous Glucose Monitors) and insulin pumps. We believe in patient choice and the importance of reducing out of pocket costs for these life changing and life saving devices.

Choose a province below to see coverage of diabetes tech and types of insulin in your province.

QC Qc BC C.-B. AB Alb. SK Sask. MB Man. ON Ont. NU Nt NT T.N.-O. YT Yn NL T.-N.-L. PEI Î.-P.-É. NB N.-B. NS N.-É.

Available Devices in Alberta

In response to the public, the government will no longer be making changes to the Insulin Pump Therapy Program. The program will continue as it was designed, and the government commits to add access to the next generation of insulin pumps starting as soon as possible this year.

  • Coverage for insulin pumps is provided through Alberta’s Insulin Pump Therapy Program and patients must:
    • be a resident of Alberta who is eligible for coverage under the Alberta Health Care Insurance Plan.
    • be diagnosed with Type 1 diabetes or Type 3c diabetes and be under the care of a physician or nurse practitioner for the condition.
    • meet and continue to meet the clinical criteria as set out in the Insulin Pump Therapy Program – Clinical Criteria.
    • complete a pre-insulin pump information session.
    • complete an insulin pump therapy (IPT) education plan.
    • attend at least one assessment at a Clinic
    • complete a Patient Responsibility Form.
    • have a completed an Eligibility Notification Form.
    • have been sent a Confirmation Letter.
    • participate in required reviews and ongoing clinical monitoring by the Clinic Team.
    • have not been sent a Letter of Clinical Ineligibility.
    • have not been sent a Discontinuation Letter.
  • Additional Information: https://www.albertahealthservices.ca/services/page8548.aspx

Coverage is provided through Alberta Blue Cross only for the FreeStyle Libre Flash Glucose Monitoring System for group plans that provide coverage for diabetic supplies. Government sponsored plans and individual plans do not currently cover FreeStyle Libre. Coverage is provided in one of the following ways by group plans:

  • Coverage for plan members who are using insulin.
  • Coverage for anyone with diabetes.
  • No coverage.
Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid Acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Short-Acting regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Insulin Lispro/lispro protamine
suspension (Humalog Mix25)
Humalog Mix50

Available Devices in British Columbia

PharmaCare provides coverage of a continuous glucose monitor (CGM) and a flash glucose monitor (FGM) through Special Authority. Initial coverage is for 1 year. After the first year, your prescriber can request a Special Authority renewal for 5 years.

You are eligible for coverage if:

  • You are covered under one (or more) of these plans:
  • Fair PharmaCare
  • Plan C (Income Assistance)
  • Plan F (At Home Program)
  • Plan W (First Nations Health Benefits)
  • Blood glucose testing with a CGM/FGM has been deemed medically necessary for you
  • You agree to comprehensive and age-appropriate diabetes education by an interdisciplinary diabetes healthcare team and commit to regular follow-up

If you are already using a CGM/FGM and would like to be covered by PharmaCare, your prescriber will still need to apply for Special Authority. You must meet the eligibility criteria. You do not need a certificate of training from a diabetes education centre to qualify for this coverage.

CGMs, FGMs and blood glucose test strips

If using a CGM/FGM, you may occasionally need blood glucose test strips (for example, if your monitor displays an error code or if your symptoms don’t match your readings). CGM and FGM users are covered for 200 blood glucose test strips per year.

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid Acting Aspart (NovoRapid) *
Glulisine (Apidra) *
Lispro (Humalog) *
Short-Acting regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Biphasic Insulin Aspart (NovoMix 30) *
Insulin Lispro/lispro protamine suspension (Humalog Mix25) *
Humalog Mix50 *

 

* BC Pharmacare provides partial reimbursement for rapid-acting insulins and patients must pay the difference

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Short-acting Pork regular insulin (Hypurin Regular)
Long-acting basal analogues Detemir (Levemir)
Pork isophane insulin (Hypurin NPH)

Note: Exceptional coverage may occur for people whose endocrinologist/ diabetes physician determines these two systems are unsuitable for them.

Available Devices in Manitoba

On March 7, 2023, as part of Budget 2023, the Government of Manitoba announced expanded insulin pump coverage for all patients with type 1 diabetes over the age of 18. Coverage for patients under the age of 18 will continue to be provided through the Manitoba Pediatric Insulin Pump Program.

Pre-approval requires the completion of a form by your endocrinologist or authorized diabetes specialist. You and your provider will assess if insulin pump therapy is appropriate for your care and if you meet the established provincial clinical criteria. Once approved, you will be able to access resources to support your choice of pump and place an order.

For more information, please visit: https://sharedhealthmb.ca/patient-care/diabetes-care/

On March 7, 2023, as part of Budget 2023, the Government of Manitoba announced expanded coverage of advanced glucose monitors (both Flash GM and CGM) for all patients with type 1 diabetes over the age of 18. Coverage for patients under the age of 18 will continue to be provided through the Manitoba Pediatric Insulin Pump Program.

Anyone with Type 1 or Type 2 diabetes requiring the use of insulin and who meets the eligibility criteria available here is eligible for an advanced glucose monitor through the Pharmacare Program. If you meet the eligibility criteria, you can speak to your provider about a prescription for an advanced glucose monitor. Once you have been provided a prescription, you can obtain an AGM device from an approved vendor or through a pharmacy of your choosing. If you choose to purchase a device through a vendor directly, you can submit your receipt for reimbursement and/or have it applied toward your Pharmacare deductible.

For more information, please visit: https://sharedhealthmb.ca/patient-care/diabetes-care/

On March 7, 2023, as part of Budget 2023, the Government of Manitoba announced expanded coverage of advanced glucose monitors (both Flash GM and CGM) for all patients with type 1 diabetes over the age of 18. Coverage for patients under the age of 18 will continue to be provided through the Manitoba Pediatric Insulin Pump Program.

Anyone with Type 1 or Type 2 diabetes requiring the use of insulin and who meets the eligibility criteria available here is eligible for an advanced glucose monitor through the Pharmacare Program. If you meet the eligibility criteria, you can speak to your provider about a prescription for an advanced glucose monitor. Once you have been provided a prescription, you can obtain an AGM device from an approved vendor or through a pharmacy of your choosing. If you choose to purchase a device through a vendor directly, you can submit your receipt for reimbursement and/or have it applied toward your Pharmacare deductible.

For more information, please visit: https://sharedhealthmb.ca/patient-care/diabetes-care/

 

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Lispro (biosimilar) (Admelog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)
Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Insulin Lispro/lispro protamine suspension (Humalog Mix25)

Available Devices in New Brunswick

Effective August 15th, 2023, the age cap on eligibility for coverage was removed, allowing people older than 25 to apply.

The New Brunswick Insulin Pump Program (NBIPP) supports New Brunswickers living with Type 1 diabetes who are medically eligible for insulin pump therapy. The program seeks to assist individuals in obtaining fair and affordable access to a range of insulin pump devices and the basic operating supplies. Additionally, NBIPP assists individuals requiring intensive insulin therapy delivered via pump therapy or multiple (3+) daily injections, in accessing continuous glucose monitoring sensors.

The client/family is responsible for a portion of the costs of the device and supplies based on income. The calculation for the client/family contribution considers household income, household size and the selected device. Insurance coverage is also considered. Only the uninsured costs of pumps, supplies and sensors are eligible for coverage under NBIPP, and the uninsured amount is income-tested.

New Brunswickers who wish to apply for income-tested coverage for their insulin pump, the operating supplies and/or CGM sensors, must meet the medical criteria and complete the NBIPP Confirmation of Medical Eligibility form together with their physician specialist. The physician specialist submits the completed form directly to the NBIPP Coordinator. Only the devices and supplies included in the Approved Vendor Lists are eligible for coverage. 

The client, or as appropriate, the legal guardian, or substitute decision maker, must complete the appropriate application form and submit along with supporting documentation to NBIPP via email: NBIPP-PPINB@gnb.ca or by mail to the address below. The application form includes income and insurance information that will be used to determine the client/family’s financial contribution.

Once the request has been approved by NBIPP, the clients will receive their devices and supplies directly from the device vendor. Clients/families pay their financial contribution for the device and supplies directly to the vendor.  Remaining costs are billed to the province by the vendor.

To learn more about the program, please see the Frequently Asked Questions (FAQ) document.  If you still have questions, you may contact the NBIPP Coordinator:

Tracadie-Sheila Hospital
400, rue des Hospitalières
PO Box 3180
Tracadie-Sheila, NB
E1X 1G5

Toll Free: 1-855-655-5525
Phone: 506-394-3382
Fax: 506-394-3381
Toll Free Fax: 1-855-290-2371

Email: NBIPP-PPINB@gnb.ca

No Coverage

Effective October 30th, 2023, financial support for continuous glucose monitoring (CGM) is available for medically eligible New Brunswickers living with Type 1 diabetes and with Type 2 diabetes on intensive insulin therapy, requiring 3 or more insulin injections per day.

The New Brunswick Insulin Pump Program (NBIPP) supports New Brunswickers living with Type 1 diabetes who are medically eligible for insulin pump therapy. The program seeks to assist individuals in obtaining fair and affordable access to a range of insulin pump devices and the basic operating supplies. Additionally, NBIPP assists individuals requiring intensive insulin therapy delivered via pump therapy or multiple (3+) daily injections, in accessing continuous glucose monitoring sensors.

The client/family is responsible for a portion of the costs of the device and supplies based on income. The calculation for the client/family contribution considers household income, household size and the selected device. Insurance coverage is also considered. Only the uninsured costs of pumps, supplies and sensors are eligible for coverage under NBIPP, and the uninsured amount is income-tested.

New Brunswickers who wish to apply for income-tested coverage for their insulin pump, the operating supplies and/or CGM sensors, must meet the medical criteria and complete the NBIPP Confirmation of Medical Eligibility form together with their physician specialist. The physician specialist submits the completed form directly to the NBIPP Coordinator. Only the devices and supplies included in the Approved Vendor Lists are eligible for coverage. 

The client, or as appropriate, the legal guardian, or substitute decision maker, must complete the appropriate application form and submit along with supporting documentation to NBIPP via email: NBIPP-PPINB@gnb.ca or by mail to the address below. The application form includes income and insurance information that will be used to determine the client/family’s financial contribution.

Once the request has been approved by NBIPP, the clients will receive their devices and supplies directly from the device vendor. Clients/families pay their financial contribution for the device and supplies directly to the vendor.  Remaining costs are billed to the province by the vendor.

To learn more about the program, please see the Frequently Asked Questions (FAQ) document.  If you still have questions, you may contact the NBIPP Coordinator:

Tracadie-Sheila Hospital
400, rue des Hospitalières
PO Box 3180
Tracadie-Sheila, NB
E1X 1G5

Toll Free: 1-855-655-5525
Phone: 506-394-3382
Fax: 506-394-3381
Toll Free Fax: 1-855-290-2371

Email: NBIPP-PPINB@gnb.ca

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (biosimilar) (Admelog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)

 

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Lispro (Humalog)
Long-acting basal analogues Detemir (Levemir)

Available Devices in Newfoundland and Labrador

  • Insulin Pumps are covered in Newfoundland and Labrador under the province’s Insulin Pump Program. Individuals must:
    • have been diagnosed with type 1 Diabetes Mellitus (T1DM);
    • be a resident of Newfoundland and Labrador;
    • have a valid medical care plan (MCP) card;
    • meet medical eligibility criteria; and
    • if 18 years of age or older, meet the requirements for financial assistance through an income testing criteria.
  • Additional Information: https://www.easternhealth.ca/find-health-care/nlipp/

No coverage

The Provincial Government and Newfoundland and Labrador Health Services (NL Health Services) are beginning a one-year pilot project to determine the feasibility of a provincial continuous glucose monitoring program.

Patients eligible for the pilot project include those:

  • With type 1 diabetes;
  • Who are under the age of 18 and/or followed by the Pediatric Diabetes Program at the Janeway Hospital;
  • For whom continuous glucose monitoring is deemed medically necessary by the Pediatric Diabetes Team or those who are using an insulin pump with hybrid closed loop software capability that can adjust insulin by using real time sensor readings; and
  • Who have a valid Newfoundland and Labrador Medical Care Plan (MCP) number.

To participate, email NLCGMP@easternhealth.ca and request an application package.

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)

 

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Lispro (Humalog)
Long-acting basal analogues Detemir (Levemir)

Available Devices in Nova Scotia

  • Insulin Pumps are covered in Nova Scotia under the province’s Insulin Pump Program for individuals who are 25 years of age and under and meet certain financial and medical criteria.
  • Additional Information: https://novascotia.ca/DHW/NSIPP/

No Coverage

No Coverage

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)

 

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Lispro (Humalog) *
Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)

 

* NS: Humalog – full benefit for children under 18

Available Devices in Northwest Territories

All ages are covered, as well as 100% of the pump supplies.

No coverage

No coverage

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)
Glargine U300 (Toujeo)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Insulin Lispro/lispro protamine suspension (Humalog Mix25)
Humalog Mix50

 

Available Devices in Nunuvut

All ages are covered, as well as 100% of the pump supplies.

No coverage

No coverage

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)
Glargine U300 (Toujeo)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Insulin Lispro/lispro protamine suspension (Humalog Mix25)
Humalog Mix50

 

Available Devices in Ontario

  • Flash GMs are covered in Ontario under the Ontario Drug Benefit for those who are:
    • 65 years old (or are 24 years of age or younger and not covered by a private insurance plan)
    • Living in a:
      • long-term care home
      • home for special care
      • Community Home for Opportunity
    • Receiving professional home and community care services
    • Receiving benefits from Ontario Works or Ontario Disability Support Program; or
    • Enrolled in the Trillium Drug Program
  • Additional Information: https://www.ontario.ca/page/get-coverage-prescription-drugs

 

  • Starting March 14, 2022, eligible Ontarians with type 1 diabetes can receive Assistive Devices Program funding for a continuous glucose monitor and the related supplies. Eligible individuals include those with type 1 diabetes who are at risk of severe hypoglycemia or who are unable to recognize, or communicate about, symptoms of hypoglycemia.
  • Additional Information: https://www.health.gov.on.ca/en/pro/programs/adp/memos/docs/CGM_QA.pdf
Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Glulisine (Apidra)
Lispro (Humalog)
Lispro (biosimilar) (Admelog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)
Glargine U300 (Toujeo)
Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Biphasic Insulin Aspart (NovoMix 30)
Insuin Lispro/lispro protamine suspension (Humalog Mix25)

 

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)

Available Devices in Prince Edward Island

Funding assistance for glucose sensor systems are accepted through the P.E.I. Glucose Sensor Program, giving Islanders access to these devices at reduced costs through local pharmacies.

Eligibility criteria:

  • a permanent resident as defined by the Drug Cost Assistance Act
  • a valid PEI Health Card
  • Filed your most recent income tax return
  • Are diagnosed by a medical practitioner or nurse practitioner as having diabetes and
  • Are reliant on an insulin pump or multiple daily injections of insulin (i.e. 3 or more) to manage your diabetes and
  • Have a signed Special Authorization form from your medical practitioner, nurse practitioner or certified diabetes educator.

Funding assistance for glucose sensor systems are accepted through the P.E.I. Glucose Sensor Program, giving Islanders access to these devices at reduced costs through local pharmacies.

Eligibility criteria:

  • a permanent resident as defined by the Drug Cost Assistance Act
  • a valid PEI Health Card
  • Filed your most recent income tax return
  • Are diagnosed by a medical practitioner or nurse practitioner as having diabetes and
  • Are reliant on an insulin pump or multiple daily injections of insulin (i.e. 3 or more) to manage your diabetes and
  • Have a signed Special Authorization form from your medical practitioner, nurse practitioner or certified diabetes educator.
Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Insulin Lispro/lispro protamine suspension (Humalog Mix25)

 

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)
Glargine U300 (Toujeo)

Available Devices in Quebec

FREESTYLE LIBRE SENSOR:

For self-monitoring of glycemia in diabetic persons aged 18 or over, who fulfil the following two criteria:

  • intensive insulin therapy (treatment by insulin pump or ≥ 3 insulin injections per day); and
  • frequent episodes of hypoglycemia in the last year, despite compliance with a glycemic management plan.

The initial request is authorized for a period of six months to assess the ability of patients to use FreeStyle Libre™ and wear the sensor. Requests for continuation of treatment are authorized for a maximum period of 12 months if the person shows
optimal use of FreeStyle Libre™, i.e. at least 70% of the time.

FREESTYLE LIBRE 2 SENSOR:

For self-monitoring of blood glucose in diabetic persons age four and over. Upon the initiation of treatment, the person:

  • under age 18 must be suffering from type 1 diabetes;
  • age 18 and over must meet the following two criteria:
    • intensive insulin therapy (treatment by insulin pump or ≥ 3 insulin injections per day); and
    • frequent episodes of hypoglycemia in the last year, despite compliance with a glycemic management plan.

The initial request is authorized for a period of six months to assess the ability of patients to use FreeStyle Libre 2™ and wear the sensor. Requests for continuation of treatment are authorized for a maximum period of 12 months if the person shows optimal use of FreeStyle Libre 2™ or FreeStyle Libre™, i.e. at least 70% of the time.

DEXCOM G6 SENSOR:

For self-monitoring of glycemia in diabetic persons aged 2 or more, upon the initiation of treatment, the person:

  • under age 18 must be suffering from type-1 diabetes;
  • age 18 and over must be suffering from type-1 diabetes and must meet one or more of the following criteria:
    • non-attainment of the value of glycated hemoglobin (HbA1c) adapted to the patient, despite optimal management of the disease; or
    • frequent episodes of hypoglycemia in the last year, despite compliance with a glycemia management plan; or
    • inability to recognize or signal hypoglycemia symptoms.

The initial request is authorized for a period of six months to assess the ability of patients to use Dexcom G6™ and wear the sensor. Requests for continuation of treatment are authorized for a maximum period of 12 months if the person shows
optimal use of Dexcom G6™, i.e. at least 70% of the time.

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Lispro (biosimilar) (Admelog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine U300 (Toujeo)
Degludec (Tresiba)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Humalog Mix50

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Long-acting basal analogues Glargine (biosimilar) (Basaglar)
Pre-mixed insulins Biphasic Insulin Aspart (NovoMix 30)
Insuin Lispro/lispro protamine suspension (Humalog Mix25)

Available Devices in Saskatchewan

  • Coverage for insulin pumps is provided through Saskatchewan Aids to Independent Living (SAIL) Insulin Pump Program. Patients must:
    • Have Type 1 diabetes
    • Have demonstrated ongoing and sustained practice of the following diabetes-related activities for a minimum of six (6) months prior to the insulin pump trial:
      • Blood glucose monitoring four (4) or more times per day or appropriate use of a continuous glucose monitor (CGM) or flash glucose monitor (FGM).
      • Consistency and accuracy in carbohydrate counting.
      • Ability to self-assess and take action based on blood glucose results.
      • Safe and effective management of hypoglycemia and hyperglycemia.
      • A commitment to long-term diabetes follow-up through regular assessments occurring at least annually (every 12 months) by a diabetes education program, diabetes educator, or their authorized specialist physician.
      • Expressed expectations or goals that are in line with potential outcomes of pump therapy.
      • No unacceptable burden of diabetic ketoacidosis as determined by a diabetes education program, diabetes educator, or their authorized specialist physician.
      • Consistent A1C monitoring at an interval of approximately every three (3) to six (6) months, or as deemed appropriate by a diabetes education program, diabetes educator, or their authorized specialist physician.
      • Those age less than 18 years:
        • There is demonstration of involvement of a parent(s)/guardian(s) in diabetes management. Child/youth/family has completed all steps of the Saskatchewan Pediatric Endocrinology and diabetes education program: Insulin Pump Assessment Process, part of which includes attendance at a Pediatric Diabetes Pump Information Session or completion of the Is Pump Therapy for Me? online modules and quiz.
      • Those age 18 years and older:
        • There is demonstration of involvement of the candidate in their personal diabetes management. The candidate has been assessed through the SHA diabetes education program process.
        • If a SHA diabetes education program requires further assistance and deems it appropriate for their client, patients may access educational training through a SAIL registered provider who is a Certified Diabetes Educator (CDE)® and also a certified insulin pump trainer, if instructed to do so by an SHA diabetes program.
    • Have completed an insulin pump trial for a period of up to three months that confirms:
      • the medical appropriateness of the insulin pump; and,
      • an adequate level of knowledge to operate the pump, and that safe use of the device has been achieved as confirmed by a certified pump trainer to the satisfaction of the SHA diabetes educator or the SAIL Registered CDE®.
    • Have eligibility certified by an SHA diabetes educator or a SAIL Registered CDE® who contributed to the assessment of the criteria; and,
      • For those less than 18 years:
        • Have eligibility certified by a pediatric licensed specialist (pediatric endocrinologist or pediatrician with diabetes expertise) who is associated with a SHA pediatric diabetes education program and has experience with insulin pump management in children.
      • For those aged 18 years and over:
        • Have eligibility certified by an endocrinologist or another specialist physician who is associated with a SHA diabetes education program and who has experience with insulin pump management.
    • Have completed the Client (parent/caregiver) Consent and Authorization and Confirmation of Responsibility on the Insulin Pump Program application.
  • Additional Information: https://www.saskatchewan.ca/residents/health/accessing-health-care-services/insulin-pump-program

Initial Criteria

For pediatric patients with diabetes (or meet criterion ‘c’ specifically below) who are under 18 years old and meet ALL of the following criteria:

  • Under the care and management of a pediatric endocrinologist, pediatric diabetes specialist, pediatric metabolic physician, or certified diabetes educator within the Saskatchewan Health Authority who is working with a pediatric diabetes specialist;
  • Patient and/or caregiver demonstrates the capacity to use the CGM/FGM appropriately;
  • Patient and/or caregiver demonstrates a reasonable understanding of what the CGM/FGM can do and how it can benefit their care; and
  • Patient and/or caregiver affirms a willingness to use the CGM/FGM properly and to use the data from this technology to make safe and effective diabetes management decisions.

In addition, patients must also meet ONE of the following:

  1. Approved for the Saskatchewan Insulin Pump Program (NOTE: The Saskatchewan Insulin Pump Program policy will determine when patients are eligible for a new insulin pump funded by the Saskatchewan Insulin Pump Program.; OR
  2. On both basal AND bolus insulin; OR
  3. Have hyperinsulinism requiring frequent blood glucose monitoring.

Initial approval duration: One year

Renewal criteria

Coverage may be continued if ALL of the following are met:

  • Patient remains under the age of 18;
  • Patient has routine follow up with their diabetes care team and remains under the care and management of a pediatric endocrinologist, pediatric diabetes specialist, pediatric metabolic physician, or certified diabetes educator within the Saskatchewan Health Authority who is involved with pediatric diabetes management;
  • Patient and/or caregiver continues to demonstrate the capacity to use the CGM/FGM appropriately;
  • Patient and/or caregiver continues to demonstrate a reasonable understanding of what the CGM/FGM can do and how it can benefit their care; and
  • Patient and/or caregiver continues to affirm a willingness to use the CGM/FGM properly and to use the data from this technology to make safe and effective diabetes management decisions.

Coverage may also be discontinued upon notification from the care provider that the CGM/FGM criteria is no longer met by this patient.

Renewal approval duration: One year

Initial Criteria

For pediatric patients with diabetes (or meet criterion ‘c’ specifically below) who are under 18 years old and meet ALL of the following criteria:

  • Under the care and management of a pediatric endocrinologist, pediatric diabetes specialist, pediatric metabolic physician, or certified diabetes educator within the Saskatchewan Health Authority who is working with a pediatric diabetes specialist;
  • Patient and/or caregiver demonstrates the capacity to use the CGM/FGM appropriately;
  • Patient and/or caregiver demonstrates a reasonable understanding of what the CGM/FGM can do and how it can benefit their care; and
  • Patient and/or caregiver affirms a willingness to use the CGM/FGM properly and to use the data from this technology to make safe and effective diabetes management decisions.

In addition, patients must also meet ONE of the following:

  1. Approved for the Saskatchewan Insulin Pump Program (NOTE: The Saskatchewan Insulin Pump Program policy will determine when patients are eligible for a new insulin pump funded by the Saskatchewan Insulin Pump Program.; OR
  2. On both basal AND bolus insulin; OR
  3. Have hyperinsulinism requiring frequent blood glucose monitoring.

Initial approval duration: One year

Renewal criteria

Coverage may be continued if ALL of the following are met:

  • Patient remains under the age of 18;
  • Patient has routine follow up with their diabetes care team and remains under the care and management of a pediatric endocrinologist, pediatric diabetes specialist, pediatric metabolic physician, or certified diabetes educator within the Saskatchewan Health Authority who is involved with pediatric diabetes management;
  • Patient and/or caregiver continues to demonstrate the capacity to use the CGM/FGM appropriately;
  • Patient and/or caregiver continues to demonstrate a reasonable understanding of what the CGM/FGM can do and how it can benefit their care; and
  • Patient and/or caregiver continues to affirm a willingness to use the CGM/FGM properly and to use the data from this technology to make safe and effective diabetes management decisions.

Coverage may also be discontinued upon notification from the care provider that the CGM/FGM criteria is no longer met by this patient.

Renewal approval duration: One year

Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Glulisine (Apidra)
Lispro (Humalog)
Short-Acting Lispro (biosimilar) (Admelog)
Regular (Humulin-R, Novolin ge Toronto)
Pork regular insulin (Hypurin Regular)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Detemir (Levemir)
Glargine (Lantus)
Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pork isophane insulin (Hypurin NPH)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)

Available Devices in Yukon

All ages are covered, as well as 100% of the pump supplies.

  • Flash GMs are covered for all ages and physicians will apply for coverage on behalf of their patients
  • If adults prefer to use a continuous glucose monitor, they can apply their flash glucose monitor coverage to the cost of a continuous glucose monitor.
  • To be eligible for the benefit, Yukoners with type 1 diabetes who meet the benefit criteria must register with the Chronic Disease and Disability Benefit program at 867-667-5092. People aged 65 or older can contact the Pharmacare program at 867-667-5403.
  • CGMs are covered for all ages and physicians will apply for coverage on behalf of their patients
  • If adults prefer to use a flash glucose monitor, they can apply their continuous glucose monitor coverage to the cost of a flash glucose monitor.
  • To be eligible for the benefit, Yukoners with type 1 diabetes who meet the benefit criteria must register with the Chronic Disease and Disability Benefit program at 867-667-5092. People aged 65 or older can contact the Pharmacare program at 867-667-5403.
Listed

Can be prescribed by any doctor. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Aspart (NovoRapid)
Glulisine (Apidra)
Lispro (Humalog)
Short-Acting Regular (Humulin-R, Novolin ge Toronto)
Pork regular insulin (Hypurin Regular)
Basal Insulins Intermediate acting – regular NPH (Humulin-N, Novolin GE NPH)
Long-acting basal analogues Glargine (biosimilar) (Basaglar)
Degludec (Tresiba)
Pork isophane insulin (Hypurin NPH)
Pre-Mixed Insulin Premixed Regular-NPH (Humulin 30/70, Novolin 30/70-40/60-50/50)
Biphasic Insulin Aspart (NovoMix 30)
Insulin Lispro/lispro protamine suspension (Humalog Mix25)
Humalog Mix50

 

 

Restricted

Only available to those who meet eligibility criteria and receive prior approval from the drug benefit plan. Cost will be fully or partially covered according to the terms of the public drug plan.

Rapid-acting Lispro (Humalog)
Long-acting basal analogues Detemir (Levemir)

No details are available for this province or territory